Talphera (TLPH) Projected to Post Earnings on Thursday

Talphera (NASDAQ:TLPH) is anticipated to issue its Q4 2025 results after the market closes on Thursday, March 5th. Analysts expect Talphera to post earnings of ($0.0750) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 24, 2026 at 4:00 PM ET.

Talphera Stock Up 9.0%

Shares of NASDAQ:TLPH opened at $0.96 on Thursday. Talphera has a twelve month low of $0.38 and a twelve month high of $1.57. The stock’s 50 day moving average is $0.98 and its 200-day moving average is $1.00. The firm has a market capitalization of $44.74 million, a price-to-earnings ratio of -2.53 and a beta of 0.46.

Insiders Place Their Bets

In other Talphera news, CEO Vincent J. Angotti acquired 105,364 shares of Talphera stock in a transaction on Thursday, February 12th. The stock was purchased at an average price of $0.81 per share, for a total transaction of $85,344.84. Following the purchase, the chief executive officer directly owned 586,954 shares of the company’s stock, valued at $475,432.74. This trade represents a 21.88% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Badri N. Dasu bought 35,000 shares of the firm’s stock in a transaction dated Thursday, February 12th. The shares were acquired at an average cost of $0.81 per share, with a total value of $28,350.00. Following the completion of the transaction, the insider owned 76,230 shares in the company, valued at approximately $61,746.30. The trade was a 84.89% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders purchased 220,364 shares of company stock valued at $178,495. Insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Talphera

Several institutional investors have recently added to or reduced their stakes in the stock. Group One Trading LLC raised its position in Talphera by 3,224.0% in the third quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock worth $27,000 after acquiring an additional 29,500 shares during the period. Virtu Financial LLC bought a new position in shares of Talphera during the 3rd quarter valued at approximately $29,000. Mariner LLC increased its stake in shares of Talphera by 132.0% during the 4th quarter. Mariner LLC now owns 58,000 shares of the company’s stock worth $66,000 after purchasing an additional 33,000 shares during the last quarter. Persistent Asset Partners Ltd bought a new stake in shares of Talphera in the 4th quarter worth approximately $42,000. Finally, Dauntless Investment Group LLC bought a new stake in shares of Talphera in the 3rd quarter worth approximately $89,000. Institutional investors own 37.67% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Wall Street Zen upgraded shares of Talphera to a “hold” rating in a report on Saturday, November 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Talphera in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $6.00.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.